4 registered trials, newest registry update first. Showing only trials linked to Eloralintide.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06603571 | Eloralintide | Phase 2 | Completed | Eli Lilly and Company | 367 | Jul 1, 2026 | Sep 29, 2026 |
| A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight NCT07808060 | Eloralintide | Phase 1 | Not yet recruiting | Eli Lilly and Company | 34 | Jun 2027 | Sep 8, 2026 |
| A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight NCT06230523 | Eloralintide | Phase 2 | Completed | Eli Lilly and Company | 263 | May 30, 2025 | Jun 24, 2026 |
| A Study of LY3841136 in Healthy and Overweight Participants NCT05295940 | Eloralintide | Phase 1 | Completed | Eli Lilly and Company | 148 | Jan 25, 2024 | Apr 1, 2024 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.
